Human trial
Mensch, kleine Phase-1/2-Studien
Teichman SL et al. 2006
Increase in growth-hormone level after administration
What does NOT follow: Pharmacodynamic effect established; long-term clinical endpoints missing.
Peptide entry · Growth
CJC-1295
CJC-1295 mit DAC · DAC:GRF · GHRH-Analog (langwirksam)
Highest evidence
Human trial
Studies recorded
3· 2 in humans
Legal status · US
Research onlyScientific context only. Not medical advice, not a recommendation to use.
At a glance
Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing.
Researched for
GH/IGF-1 increaseBody composition (theoretical)Anti-aging (anecdotal)Recovery (anecdotal)
Official status
US: Research only
Not approved as a medicinal product; marketed only as a research chemical.
01
Mechanism of action
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
Human trial
Mensch, kleine Studien
Teichman SL et al. 2006
Elevated IGF-1 level
What does NOT follow: Surrogate marker for GH activity — does not directly speak to endpoints like muscle gain or body composition.
Anecdotal
—
Claimed change in body composition (muscle gain / fat loss)
What does NOT follow: Outside case reports in fitness communities, no controlled human studies on body-composition endpoints.
04
Where studies disagree
Open question
Do elevations of GH/IGF-1 translate into clinically relevant human endpoints?
POSITION A
Pharmacodynamic data and mechanistic plausibility argue for effects on body composition.
POSITION B
Direct clinical endpoint trials (muscle mass, function, health outcomes) are missing.
CURRENT STATE · Surrogate effects are established; clinical endpoints are not.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 144 h. Pure pharmacokinetic model — not a dosing recommendation.
Open in PK tool →Start time: t₀ = 0.0d
Repeat interval: off (single dose)
06
Routes of administration in the literature
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
Standard route in published human studies.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human trial
Water retention
Consistent with elevated GH activity; clinical relevance dose-dependent.
ungewöhnlich / uncommon
Human trial
Injection-site reactions
Described in phase-1 data; frequency in long-term use unclear.
vereinzelt / sporadic
Theoretical
Theoretical risk of proliferative effects from elevated IGF-1
Mechanistically inferred; not established in clinical studies. Long-term safety data are absent.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Confusion with Modified GRF (1-29)
Non-pharmaceutical sources use "CJC-1295" inconsistently — sometimes with DAC (long-acting), sometimes as Mod GRF 1-29 without DAC (short-acting). Identity testing is the only reliable distinction.
WADA status
GHRH analogues are on the WADA Prohibited List — relevant for competitive sport.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Improved sleep and faster recovery
Common claim in fitness and anti-aging communities
Not supported by studies: Subjective self-reports without blinding; no controlled studies on these endpoints.
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
14
Study register
Human trialControlled trialn = 21
Teichman SL et al. · 2006
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
SampleHealthy adults.
EndpointGH and IGF-1 concentration time course after single dose.
MethodSingle subcutaneous administration with escalating doses in the microgram-per-kilogram range. Follow-up of GH and IGF-1 levels over several days.
Findings:Sustained elevation of GH and IGF-1 over several days.
Limitations:Small sample, short observation, surrogate-oriented endpoints.
Human trialControlled trialn = 7
Ionescu M, Frohman LA · 2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
SampleHealthy adults under several weeks of observation.
EndpointPulsatility of GH secretion under continuous CJC-1295 exposure.
MethodRepeated subcutaneous administration; continuous GH measurement to assess pulsatility.
Concrete results
GH pulse frequency
erhalten / preserved
Baseline
Findings:GH pulses were preserved over the observation period, with elevated baseline.
Limitations:Very small sample, no clinical endpoints recorded.
Animal modelControlled trial
Alba M. et al. · 2006
Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse
Findings:Growth normalisation in the animal model; evidence for functional activity of the DAC modification.
Limitations:Animal model — translation to adults with intact GH axis is not direct.
15
Sources & method
Reviewed by
Dr. [Placeholder]
Last reviewed
2026-05-21
Get new studies on CJC-1295
Science only, no sales. Unsubscribe anytime.